开发DuoMYC:一种合成的细胞透型小蛋白质,可以有效抑制致癌转录因子MYC
Brecht D Ellenbroek1,2, Jan Pascal Kahler1,2, Damiano Arella1,2
1Leiden University, 2333, CC Leiden, The Netherlands.
Angewandte Chemie (International ed. in English)
|September 24, 2024
概括
科学家们设计了合成微蛋白来准MYC瘤蛋白,这是一个具有挑战性的癌症标. 主导的小蛋白DuoMYC有效地抑制癌细胞内MYC驱动的转录.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- MYC转录因子是一个主调节器,涉及到许多人类癌症.
- 由于缺乏经典的结合口袋和存在内在无序的区域,MYC被认为是"不可治疗的".
- 准MYC是癌症药物开发中的一个重大挑战.
研究的目的:
- 设计能够抑制MYC驱动转录的新型合成小蛋白.
- 开发一种针对MYC的替代治疗策略,克服其"无药"的地位.
- 评估工程微蛋白在抑制癌细胞中MYC活性方面的有效性.
主要方法:
- 合成微蛋白的基于结构的设计.
- 固态阶段合成和特定站点的交叉链接,以创建小蛋白质.
- 使用记者基因测定和RNA测序来评估DNA结合亲和力 (KD) 和细胞功效 (IC50).
主要成果:
- 工程微蛋白成功地与MYC目标DNA序列 (E-Box) 结合,并具有很高的亲和力.
- 领先的变体DuoMYC在抑制细胞内MYC驱动的转录方面表现出亚微分子功效.
- 与最近开发的其他MYC抑制剂相比,DuoMYC表现出更高的疗效.
结论:
- 工程合成小蛋白代表了一种有前途的治疗方法,用于向像MYC这样具有挑战性的细胞内蛋白质.
- 这一策略为癌症治疗中直接抑制MYC提供了可行的替代方案.
- DuoMYC的开发突出了合成蛋白治疗在瘤学的潜力.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K


